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, Gabriel S 1 , Boccuzzi S 2 1 Sanofi-Aventis, Bagneux Cedex, France; 2 PharMetrics, Inc, Watertown, MA, USA OBJECTIVES: Atrial fibrillation (AF) remains a major health problem, affecting 2.2 million adults in the US with an estimated cost burden of $3 billion annually. Treatment approaches vary significantly and can include both interventional and pharmacologic options. The purpose of this research was to characterize the clinical and economic impact associated with AF. METHODS: Patients with continuous health benefit eligibility and a "new" diagnosis of AF (ICD-9-CM 427.3¥) were identified from a large, geographically diverse administrative claims database in the US (N = 43 million) between 1 January 2000 and 31 December 2001 with a variable follow-up period of ≥6 months. Warfarin-treated (WT) (N = 6,846) and untreated (UT) (N = 40,849) cohorts were evaluated based on initial therapy associated with the AF diagnosis. Study outcomes included patient demography, treatment patterns and direct medical costs.
RESULTS:
The AF cohorts were comprised of 58.5% males with a mean age of 57.9 ± 15.8 yrs; mean duration of follow-up was 20 months. WT was initially received by 14% of this AF cohort with only 37% receiving warfarin sometime during follow-up. The WT cohort spent approximately 34% of their study followup exposed to warfarin (average number of days on therapy = 206.5; average study duration = 608.7 days). Annualized AFrelated costs were $10,560 ± 290 (WT) versus $10,131 ± 143 (UT). CONCLUSIONS: Significant proportions of AF patients do not receive pharmacotherapy. Furthermore, pharmacotherapy appeared to be sub-optimal among those who received it. Better management of AF pharmacotherapy or uses of newer therapies that provide appropriate anticoagulation are necessary to reduce the burden associated with this costly disease. Fondazione Medtronic Italia, Sesto San Giovanni (MI), Italy OBJECTIVE: Atrial Tachyarrhythmias (ATs) currently represents a major economic burden for society. Italian data on epidemiology and hospital costs of (ATs) are lacking. METHODS: Prospective systematic evaluation of all consecutively Emergency Room (ER) admitted patients with a diagnosis of AT in the Alessandria, Novara, Novi Ligure and Tortona Hospitals from November 2004 to January 2005. A group of clinicians and economists developed an ad-hoc questionnaire in order to collect data on hospital resources consumption. RESULTS: A total of 201 patients were enrolled in the study (mean age: 66.2 "b 15.4), of which 48.8% was male. Most of the patients (80.4%) were admitted the ER in the first 48 hours after the AT event. Out of the 201 patients (44.3%) declared that was their first AT episode.
PCV13 EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS
At the moment of the event 46.7% of the patients were not assuming any pharmacological therapy, 21.9% were assuming anti-aggregate, 7.5% anticoagulant, 39.8% anti-arrhythmic drugs and 5% were already implanted with a Pacemaker. A total of 818 diagnostic test and therapeutic procedures were performed, which means, on average, 4.1 per patient. The most performed were ECG followed by blood test, pharmacological cardioversion, chest X-ray, in-hospital ECG monitoring, 24-hour holter monitoring, and external cardioversion. Out of the total patients, 148 were discharged from the ER, 31 patients were hospitalized in the "department of short-term observation" (average length of staying (LOS): 1.3 days), 8 patients were hospitalized in the cardiological department (average LOS: 7 days), 12 were hospitalized in other departments (average LOS: 4 days) and only 2 patients had different destination. CONCLUSIONS: This study shows that ATs, even if they are not life-threatening diseases and most patients are discharged directly from ER, absorb a relevant amount of hospital resources. Future economic evaluation of this data will highlight also the impact of ATs on the hospital and NHS expenses.
